{"name":"Metagenomi","slug":"metagenomi","ticker":"Private","exchange":"Private","domain":"metagenomi.co","description":"Metagenomi is a private gene editing company focused on developing novel gene editing technologies. The company is working on several gene editing platforms and has a strong pipeline of therapeutic candidates. As a private company, Metagenomi does not publicly disclose detailed financial information, but it has received significant funding from investors. Metagenomi's gene editing technologies have the potential to treat a wide range of genetic diseases.","hq":"Emeryville, CA","founded":0,"employees":"","ceo":"Brian Thomas","sector":"Gene Editing / Platform Technology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$400M (est. last round)","metrics":{"revenue":25210000,"revenueGrowth":-51.8,"grossMargin":0,"rdSpend":94433000,"netIncome":-87868000,"cash":221103000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Metagenomi Raises $150M in Series C Funding","summary":"Metagenomi announced that it has raised $150 million in Series C funding to support the development of its gene editing technologies.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"trial","headline":"Metagenomi Initiates Phase 1 Clinical Trial for MGMI-101","summary":"Metagenomi announced that it has initiated a Phase 1 clinical trial for MGMI-101, a gene editing therapy for the treatment of sickle cell disease.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQc21Tc1VYcTNnZHBXMHpRMmE4T3JBaHRnN2JBM2lTYkJhRjZ6RU5FYmdxLWRpVEx2SWFiZ2lYSW9odTNRWTZHUl9fbGdzYmNaU0h2Y1pLNTNLdmJsRU9RaW9hT3AzWVk0RHUzRk1DRGV3ZDFCeHZuYlItamo4Q1NMaW42cFo2S1UwR3BlcDBTdVZhd0pRRVpzRThKUkhnWmRjTDRleXVmLXhFS0JkU3lJcjVXTmM?oc=5","date":"2025-11-13","type":"pipeline","source":"Pharmaceutical Technology","summary":"Metagenomi culls 25% of its workforce and replaces CEO in reshuffle - Pharmaceutical Technology","headline":"Metagenomi culls 25% of its workforce and replaces CEO in reshuffle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5EeGMtTTZTLW9meGlwWTJLdzVBdk5TUFl2SC04LVRURGhabHZsTk5ldmx1MVRDalNORHBoVW4zRjlwdlEwZExWdzRNRVBPVnI1WHlJ?oc=5","date":"2025-11-12","type":"pipeline","source":"FirstWord Pharma","summary":"CEO shuffle at Ovid, Metagenomi - FirstWord Pharma","headline":"CEO shuffle at Ovid, Metagenomi","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPY1ZNcERMaThaY09QS3NQeWxHREkxOFRWNGFBSG5yUk9IWFlWUUFkMXJKN280SGRNbXFfaDFGWTR3aXVsTFlEWW9zZlhiQVY4bDlVUXpsam9tal84V3lEc1U2TVQwMkg3bmNDRjJPa1RodDB3RndnZTU5TXVMeDVSbGpIcUxtVTRJb0QtLW9HUGg5VkJPakkyVA?oc=5","date":"2025-07-31","type":"pipeline","source":"BioPharma Dive","summary":"Venture firm Frazier closes $1.3B fund for early-stage biotech investing - BioPharma Dive","headline":"Venture firm Frazier closes $1.3B fund for early-stage biotech investing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNVWNGTG9zaHZDTG9RbEJoQ1E5TldqRE9mWG1XbDV1aENPMGlRUHlpbjdjNW5Za2lxcnFFT3g4dTNZTHNLRkRGclB3QnNnOC1SQjNrQUhOVVhFVlE0ZUI2MkZTcklCOVFtbHN6dVFNdk9aNm5GdG1hZFVvRjNfbElHdmV6dzR6RWVOQzlVX1phbw?oc=5","date":"2023-08-21","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Techbio landscape: Insights into AI and genomics in pharma - drugdiscoverytrends.com","headline":"Techbio landscape: Insights into AI and genomics in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQV3EtQjJMbS16ZnpXT0w0MEpiVE1zZjRrbHVZb1lYRDVETVJPbWJoOG5VbERDWW1tMjlfVU5ucjZFb2RuY3JmdmNKZ1BQdERVT0FfUlMtdEJ0SHhtZHZmVF93RDNlX1NfLXBRSWhaOVRuTVd6WXN2NEJjVUxkTGxQOEZEanFnS3AxY182bQ?oc=5","date":"2022-11-14","type":"pipeline","source":"BioPharma Dive","summary":"Ionis teams with Metagenomi and dives into gene editing - BioPharma Dive","headline":"Ionis teams with Metagenomi and dives into gene editing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Genetic Diseases","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":25210000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":25210000,"period":"2025-12-31"},{"value":52295000,"period":"2024-12-31"},{"value":52295000,"period":"2024-12-31"},{"value":44756000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":94433000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-87868000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":221103000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}